Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IC135
- Development stage
- Preclinical
- Lead developer
- University Hospital Tübingen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IC135 is an experimental immunocytokine designed for the treatment of acute myeloid leukemia (AML). It consists of an Fc-optimized monoclonal antibody targeting CD135 (also known as FLT3) fused to wild-type interleukin-15 (IL-15). The construct is intended to concentrate IL-15 activity at the site of leukemic cells, thereby stimulating natural killer (NK) cell proliferation and enhancing antibody-dependent cellular cytotoxicity (ADCC) against the tumor. While IC135 demonstrates potent anti-leukemic activity in preclinical models, its use of wild-type IL-15 allows for binding to the IL-15 receptor alpha (IL-15Rα) on healthy cells, which can lead to non-specific immune activation and off-target toxicity. This profile led to the development of modified versions, such as MIC135, which aim to restrict IL-15 activity solely to the target-cell interface.
- Other names
- anti-CD135-IL-15 immunocytokineanti-CD-135-IL-15 immunocytokineanti-CD 135-IL-15 immunocytokineFLT3-IL-15 immunocytokineFLT-3-IL-15 immunocytokineFLT 3-IL-15 immunocytokine
Beyond the preview
Go deeper on IC135.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IC135.